89 136

Cited 0 times in

Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model

 Hyeok-Jun Yun  ;  Jin-Hong Lim  ;  Sang-Yong Kim  ;  Seok-Mo Kim  ;  Ki-Cheong Park 
 BIOMEDICINES, Vol.10(8) : 1901, 2022-08 
Journal Title
Issue Date
apoptosis ; cisplatin ; cytochrome c ; patient-derived medullary thyroid carcinoma ; sorafenib
Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localized disease is about 95%, whereas that of patients with local phase disorder is around 75%. Only 20% of patients with distant metastasis to lung at diagnosis survive 10 years, which is notably lower than survival for well-differentiated thyroid carcinoma (WDTC). The management of MTC with distant metastasis to lung could be re-surgery or chemotherapy. In this research, we planned to assess the in vitro and in vivo combinational anticancer effect of a novel combination of low-dose cisplatin and sorafenib in patient-derived MTC. The patient-derived MTC cell lines YUMC-M1, M2, and M3 were isolated and treated with a combination of cisplatin and sorafenib or either agent alone. Cisplatin and sorafenib acted in combination to forward tumor restraint compared with each agent administered alone at a low dose. Therefore, a combination of cisplatin and sorafenib could be a new therapeutic approach for MTC.
Files in This Item:
T202204423.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Seok Mo(김석모) ORCID logo https://orcid.org/0000-0001-8070-0573
Park, Ki Cheong(박기청) ORCID logo https://orcid.org/0000-0002-3435-3985
Yun, Hyeok Jun(윤혁준) ORCID logo https://orcid.org/0000-0001-6004-0782
Lim, Jin Hong(임진홍)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.